XenoPort to Release Fourth Quarter and Year-End Financial Results on March 11, 2013

  XenoPort to Release Fourth Quarter and Year-End Financial Results on March
  11, 2013

Business Wire

SANTA CLARA, Calif. -- March 4, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its fourth
quarter financial results on March 11, 2013 at approximately 4:30 p.m. Eastern
Time. The company will host a conference call at 5:00 p.m. Eastern Time that
same day. A replay of the call will be available for one week following the

To access the conference call via the Internet, go to www.XenoPort.com. Please
join the call at least 15 minutes prior to the start to ensure time for any
software downloads that may be required.

To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417. The
reference number to enter the call is 19426152.

The replay of the conference call may be accessed that same day after 8:00
p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at
1-855-859-2056 for domestic callers, or 404-537-3406 for international
callers. The reference number to enter the replay of the call is 19426152.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant® (gabapentin
enacarbil) Extended-Release Tablets is approved in the United States for the
treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults
and for the management of postherpetic neuralgia in adults. GlaxoSmithKline
holds commercialization rights for Horizant in the United States during a
transition period ending on April 30, 2013, following which XenoPort will be
responsible for the further development, manufacturing and commercialization
of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is
approved and is being marketed for the treatment of RLS in Japan. Astellas
Pharma Inc. holds all development and commercialization rights for Regnite in
Japan and five other Asian countries. XenoPort holds all other world-wide
rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates
includes potential treatments for patients with spasticity, Parkinson’s
disease and relapsing-remitting multiple sclerosis. To learn more about
XenoPort, please visit the Website at www.XenoPort.com.

XENOPORT, Horizant and Regnite are registered trademarks of XenoPort, Inc.



XenoPort, Inc.
Jackie Cossmon, 408-616-7295
Press spacebar to pause and continue. Press esc to stop.